FATEのチャート
FATEの企業情報
| symbol | FATE |
|---|---|
| 会社名 | Fate Therapeutics Inc （フェイト・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 フェイト･セラピューティクス(Fate Therapeutics Inc)は臨床段階のバイオ医薬品会社である。同社はがんおよび免疫障害のためのプログラム細胞免疫療法の開発に従事する。同社の細胞治療パイプラインは改変誘導多能性細胞による癌免疫療法を含む免疫腫瘍学プログラム、造血細胞移植を受けている患者の免疫系を保護し、自己免疫を抑制するための造血細胞免疫療法を含む免疫調節プログラムを含む。リード臨床プログラムはプログラム免疫調節細胞療法であるProTmuneである。同社は細胞プログラミング手法を利用して、CD34 +細胞、ナチュラルキラー（NK）細胞およびT細胞などの免疫細胞をプログラムする。養子細胞治療プログラムは、治療機能を調節し、免疫細胞のフェイトを導くために適用される同社の体外細胞プログラミングアプローチに基づく。 フェイト・セラピュ―ティクスは、米国のバイオベンチャ―企業。幹細胞関連で先進的な医薬品の創製を目指す。造血幹細胞の移植後の定着を高める作用を持つ幹細胞調整薬｢FT 1050｣の開発などに注力。なお、人工多能性幹細胞(iPS細胞)の作製にかかわる実験法の特許を所有する。本社は、カリフォルニア州サンディエゴ。 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA. |
| 本社所在地 | 3535 General Atomics Court Suite 200 San Diego CA 92121 USA |
| 代表者氏名 | William H. Rastetter ウィリアムH.ラスターセッター |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-875-1803 |
| 設立年月日 | 39173 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 80人 |
| url | www.fatetherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fate |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -55.14200 |
| 終値（lastsale） | 14.96 |
| 時価総額（marketcap） | 799151067.44 |
| 時価総額 | 時価総額（百万ドル） 888.97060 |
| 売上高 | 売上高（百万ドル） 4.10600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 825.80060 |
| 当期純利益 | 当期純利益（百万ドル） -56.97000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Fate Therapeutics Inc revenues remained flat at $2.1M. Net loss increased 71% to $33.8M. Revenues reflect market conditions. Higher net loss reflects Research_Development increase of 81% to $26.6M (expense) Other general_Administrative Expenses increase of 24% to $6.2M (expense) Stock-based Compensation in SGA increase of 75% to $1.2M (expense). |
FATEのテクニカル分析
FATEのニュース
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE 2023/03/04 16:11:00 Kwhen Finance
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE 2023/03/04 16:11:00 PR Newswire
NEW YORK, March 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). A class action has already…
Fate Therapeutics to Present at Upcoming March Investor Conferences 2023/03/03 21:01:00 GlobeNewswire
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
Life-Changing stocks: Fate Therapeutics, Inc. (NASDAQ:FATE), BigBear.ai Holdings, Inc. (NYSE:BBAI) 2023/03/03 08:18:39 Stock Equity
FATE has seen its SMA50 which is now -16.91%. In looking the SMA 200 we see that the stock has seen a -69.83%. BBAI has seen its SMA50 which is … The post Life-Changing stocks: Fate Therapeutics, Inc. (NASDAQ:FATE), BigBear.ai Holdings, Inc. (NYSE:BBAI) appeared first on Stocks Equity .
The Fate Therapeutics Inc. (NASDAQ: FATE) Stock Price: Is It Overvalued? 2023/03/02 13:30:00 Stocks Register
Fate Therapeutics Inc. (NASDAQ:FATE) shares, rose in value on Wednesday, 03/01/23, with the stock price down by -0.49% to the previous day’s close as strong demand from buyers drove the stock to $6.09. Actively observing the price movement in the last trading, the stock closed the session at $6.12, falling within a range of $6.085 … The Fate Therapeutics Inc. (NASDAQ: FATE) Stock Price: Is It Overvalued? Read More »
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm 2023/02/04 02:00:00 GlobeNewswire
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bioventus Inc. (NASDAQ: BVS), ESS Tech, Inc. (NYSE: GWH, GWH.WT), International Business Machines Corporation (NYSE: IBM), and Fate Therapeutics, Inc. (NASDAQ: FATE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc. 2023/02/02 22:19:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $FATE #FATE--Fate Therapeutics, Inc. (FATE) Misrepresented the Impact of the Janssen Collaboration Agreement on its Long-Term Clinical and Commercial Profitability
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders 2023/01/31 19:43:00 GlobeNewswire
BENSALEM, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Fate Therapeutics, Inc. (NASDAQ: FATE) Investor Notice: Lawsuit Alleges Securities Laws Violations 2023/01/31 16:47:00 SBWire
A lawsuit was filed on behalf of investors in Fate Therapeutics, Inc. (NASDAQ: FATE) shares over alleged securities laws violations. San Diego, CA -- ( SBWIRE ) -- 01/31/2023 -- An investor, who purchased NASDAQ: FATE shares, filed a lawsuit against Fate Therapeutics, Inc over alleged violations of Federal Securities Laws. Investors who purchased shares of Fate Therapeutics, Inc. (NASDAQ: FATE) have certain options and for certain investors are short and strict deadlines running. Deadline: March 22, 2023. NASDAQ: FATE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The plaintiff claims that between April 2, 2020 and January 5, 2023, the Defendants made false and/or misleading statements and/or failed to disclose that the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors, that accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources, that as a result, Fate had overstated the impact of the Janssen Collaboration Agreement''s on Fate''s long-term clinical and commercial profitability, and that as a result, the Company''s public statements were materially false and misleading at all relevant times.
NOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FATE 2023/01/30 21:10:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Fate business and prospects, resulting in its stock trading at inflated prices.
RGNX, FATE and ALVR are among after hours 2022/05/06 21:50:34 Seeking Alpha
Gainers: REGENXBIO (RGNX) +8%. Passage Bio (PASG) +6%
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2022 Results - Earnings Call Transcript 2022/05/05 03:53:05 Seeking Alpha
Fate Therapeutics, Inc. (NASDAQ:NASDAQ:FATE) Q1 2022 Earnings Conference Call May 4, 2022 17:00 ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko…
Fate Therapeutics GAAP EPS of -$0.68 beats by $0.11, revenue of $18.4M beats by $9.39M 2022/05/04 20:05:38 Seeking Alpha
Fate Therapeutics press release (NASDAQ:FATE): Q1 GAAP EPS of -$0.68 beats by $0.11.Revenue of $18.4M (+65.2% Y/Y) beats by $9.39M.